CKD beats expectations; Goldman Sachs reiterates Buy and raises target price to ¥10,000

Overview

This report is Goldman Sachs' earnings review of CKD. It notes that CKD posted FY3/26 operating profit of ¥19.6bn, significantly above Goldman Sachs' estimate and the market consensus; within this, the components business, supported by recovering semiconductor demand, delivered record quarterly operating profit and near-historical peak margins in 4Q. Goldman Sachs believes FY3/27 guidance is conservative, and that CKD still has room for further earnings upgrades and valuation expansion given order trends, higher capacity utilization, overseas capacity expansion, and management's focus on margins and capital efficiency.

Core views

Goldman Sachs' core view is that CKD is the FA stock with the highest semiconductor exposure in its Japan machinery coverage and is therefore best positioned to benefit from the structural upcycle in AI and semiconductors; FY3/26 results confirmed its earnings leverage; FY3/27 guidance is close to market expectations, but given the company's historically conservative guidance, there is still clear room for upside; the sales, margin, ROE, and shareholder return targets in the medium-term plan and long-term vision are conservative, but management's use of phrasing such as 'or higher' suggests a more proactive capital-markets communication stance and capital management approach.

Analysis framework

The report uses an earnings surprise analysis, a comparison of company guidance versus consensus, assessment of segment margins and capacity utilization, judgment on semiconductor-cycle exposure, and an EV/EBITDA relative valuation approach. The target price is based on FY3/28E EV/EBITDA mean, using the industry average 10x EV/EBITDA and assigning a 30% relative premium.

Methodology notes

• Valuation methodsEV/EBITDA relative valuation

  Based on FY3/28E EV/EBITDA, using the industry average multiple plus a relative premium.

  Goldman Sachs moved CKD's 12-month target-price base year from the FY3/27-28 average to FY3/28, and raised the relative premium to the sector from 0% to 30%, reflecting semiconductor exposure, earnings upgrades, and valuation re-rating.

• Earnings analysisSurprise analysis

  Compare actual results, company guidance, Goldman Sachs estimates, and I/B/E/S consensus.

  FY3/26 operating profit of ¥19.6bn exceeded Goldman Sachs' estimate of ¥18.0bn and consensus of ¥17.7bn; FY3/27 company guidance of ¥24.5bn is close to consensus of ¥24.3bn, but Goldman Sachs believes it is conservative.

• Factor frameworkGS Factor Profile

  Compare stocks across growth, financial returns, valuation multiples, and composite factors.

  Goldman Sachs disclosed that its factor framework uses sales, EBITDA, and EPS growth, ROE, ROCE, CROCI, as well as P/E, P/B, and EV/EBITDA metrics to form percentile rankings.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• CKD (6407.T)

  Core coverage name

  Strengths

  Highest semiconductor exposure among Japan FA stocks, improving components business margins, strong global fluid-control competitiveness, and room to expand capacity in China and Malaysia.

  Weaknesses

  Earnings are still affected by silicon-cycle volatility, and FY3/27 official guidance is below Goldman Sachs' earlier more optimistic estimate.

  Comparison

  Goldman Sachs believes CKD is still inexpensive relative to other FA stocks, but its semiconductor exposure and earnings leverage are more pronounced.

  Risks

  Semiconductor demand weaker than expected, rising raw-material costs, and fixed-cost growth faster than expected.

• Japan FA / machinery peers

  Relative valuation and coverage-universe reference

  Strengths

  The industry benefits from the semiconductor and AI-related capex cycle.

  Weaknesses

  Different companies have varying semiconductor exposure and earnings leverage.

  Comparison

  Goldman Sachs views CKD as the FA stock in coverage with the highest semiconductor exposure and still room for valuation re-rating.

  Risks

  Some of the industry's valuation expansion already reflects cyclical recovery, and prices could pull back if orders or margins disappoint.

Key data

• FY3/26 operating profit¥19.6bnAbove Goldman Sachs' estimate of ¥18.0bn and the I/B/E/S consensus of ¥17.7bn.
• FY3/26 4Q components business operating profit¥6.8bnA quarterly record high, with OPM at 17.0%, the second-highest level in history.
• FY3/27 company operating profit guidance¥24.5bnClose to the I/B/E/S consensus of ¥24.3bn; Goldman Sachs believes the assumptions are conservative.
• FY3/27 Goldman Sachs operating profit estimate¥29.0bnThe chart shows Goldman Sachs' estimate above company FY3/27 guidance of ¥24.5bn.
• FY3/28 Goldman Sachs operating profit estimate¥37.0bnGoldman Sachs expects FY3/28 revenue of ¥216.0bn and EBITDA of ¥45.4bn.
• Target price¥10,000Raised from ¥6,800, implying 47.3% upside.
• Medium-term targetsFY3/29 sales of ¥190bn+, OPM 13.7%+, ROE 10%+Goldman Sachs believes these targets are conservative, and management is signaling even higher goals.
• Shareholder returnsDividend payout ratio floor of 40%CKD has established a 40% minimum dividend payout ratio and indicated an intention to discuss total shareholder return going forward.

Impact & implications

The report is positive for CKD's investment case: the earnings beat and improving semiconductor demand raise earnings visibility, and the components business has higher margin upside as capacity utilization and product mix improve; although the medium-term plan's numbers are conservative, management's comments on margins, ROE, cost of capital, buybacks, and leverage have improved capital-markets communication quality. Goldman Sachs therefore raised earnings estimates, increased the relative valuation premium, and reiterated Buy.

Risks

• Semiconductor demand weaker than expected.
• A sharp rise in input costs.
• Fixed-cost growth faster than expected, compressing margins.
• Silicon-cycle volatility causing revenue and profit swings.
• If capacity expansion in China, Malaysia, and other regions is slower than expected, growth realization may be affected.

What to watch

• Whether FY3/27 actual operating profit significantly exceeds the company's ¥24.5bn guidance.
• Whether components business sales and OPM continue to stay above the historical peak range.
• Improvement in capacity utilization in China and progress on the Malaysia plant expansion.
• Whether semiconductor orders and AI-related demand remain on an uptrend.
• Whether management delivers on ROE improvement, buybacks, leverage usage, and total shareholder return discussions.
• Whether the 30% valuation premium versus peers can continue to be supported by earnings upgrades.